Phase II investigation of a PARP inhibitor (olaparib) in castration resistant prostate cancer (CRPC) which incorporates the possibility that treatment effect may be restricted to biomarker defined subgroups

Detalles Bibliográficos
Autores principales: A’Hern, Roger, DeBono, Johann, Sandhu, Shahneen, Kalaitzaki, Eletheria, Usdin, Martine, Hall, Emma E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Oral Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3287808/
http://dx.doi.org/10.1186/1745-6215-12-S1-A88

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3287808/
http://dx.doi.org/10.1186/1745-6215-12-S1-A88

Ejemplares similares